AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2018
May 11, 2018
29828_dirs_2018-05-11_c23e919e-8d7d-48b2-85c3-d5ffcb135501.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2018-05-09
Reporting Person: MARTIN JOHN C (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-09 | Non-qualified Stock Option (Right to Buy) | $65.69 | A | 9496 | Acquired | 2028-05-09 | Common Stock (9496) | Direct |
| 2018-05-09 | Restricted Stock Unit | $ | A | 2283 | Acquired | Common Stock (2283) | Direct |
Footnotes
F1: 25% of the shares subject to the option vest on each three-month anniversary measured from May 9, 2018 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 9, 2019 or the day immediately preceding the next regular annual stockholders meeting.
F2: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F3: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting.